Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Liabilities and Shareholders Equity (2016 - 2025)

Wave Life Sciences' Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $638.5 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 81.29% year-over-year to $638.5 million; the TTM value through Dec 2025 reached $1.4 billion, up 23.01%, while the annual FY2025 figure was $638.5 million, 81.29% up from the prior year.
  • Liabilities and Shareholders Equity reached $638.5 million in Q4 2025 per WVE's latest filing, up from $241.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $638.5 million in Q4 2025 to a low of $146.4 million in Q4 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $255.6 million, with a median of $232.6 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: plummeted 35.33% in 2021, then soared 87.82% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $207.0 million in 2021, then decreased by 29.28% to $146.4 million in 2022, then skyrocketed by 87.82% to $274.9 million in 2023, then increased by 28.1% to $352.2 million in 2024, then surged by 81.29% to $638.5 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Liabilities and Shareholders Equity are $638.5 million (Q4 2025), $241.4 million (Q3 2025), and $252.4 million (Q2 2025).